Payment overview · 2025
General Payments
$877.05
40 reported records · 14 companies
Healthcare provider profile · identity verified
John R Willard, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · CENTENNIAL, CO · NPI 1528124369
Verified facts
What the public records show
CMS Open Payments records show John R Willard, D.O. received $877.05 in general payments during 2025 across 40 reported records.
ABBVIE INC. accounted for 37.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $329.49 | 37.6% | 17 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $146.57 | 16.7% | 3 | 2025 |
| Saluda Medical Americas, Inc. | Unresolved — no canonical attribution shown | $70.40 | 8.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $58.88 | 6.7% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $45.77 | 5.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $45.61 | 5.2% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $37.59 | 4.3% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.60 | 3.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $29.51 | 3.4% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$22.14 | 2.5% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $18.14 | 2.1% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $14.36 | 1.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.29 | 1.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.70 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $877.05 | 40 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $223.81 | 12 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $210.41 | 11 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $119.08 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $119.08 | 1 | 2025 |
Source payment records
|
|||||
| Evoke Normalized: evoke |
Device | Saluda Medical Americas, Inc. | $70.40 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $58.88 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $58.88 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $45.77 | 3 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $37.59 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.60 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.60 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $29.51 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $29.51 | 2 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $22.14 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $18.14 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $18.14 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $14.36 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.29 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.70 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $13.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
104 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
64 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
28 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 784 | 219 |
| Levothyroxine Sodium | Levothyroxine Sodium | 382 | 112 |
| Amlodipine Besylate | Amlodipine Besylate | 272 | 77 |
| Losartan Potassium | Losartan Potassium | 265 | 71 |
| Lisinopril | Lisinopril | 214 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 198 | 61 |
| Omeprazole | Omeprazole | 178 | 56 |
| Metformin Hcl Er | Metformin Hcl | 158 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 144 | 38 |
| Simvastatin | Simvastatin | 141 | 41 |
| Metformin Hcl | Metformin Hcl | 131 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 131 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 111 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 111 | 39 |
| Allopurinol | Allopurinol | 110 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 107 | 31 |
| Synthroid | Levothyroxine Sodium | 104 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 103 | 31 |
| Alprazolam | Alprazolam | 96 | 24 |
| Trazodone Hcl | Trazodone Hcl | 92 | 24 |
| Meloxicam | Meloxicam | 90 | 35 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 85 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 81 | 25 |
| Tramadol Hcl | Tramadol Hcl | 76 | 17 |
| Bupropion Xl | Bupropion Hcl | 72 | 19 |
| Eliquis | Apixaban | 64 | 21 |
| Gabapentin | Gabapentin | 62 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 57 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 55 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 54 | 47 |
| Clonazepam | Clonazepam | 54 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 54 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 15 |
| Azithromycin | Azithromycin | 51 | 38 |
| Carvedilol | Carvedilol | 51 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 51 | 12 |
| Montelukast Sodium | Montelukast Sodium | 51 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 45 | 14 |
| Finasteride | Finasteride | 43 | 11 |
| Lorazepam | Lorazepam | 42 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 42 | 12 |
| Ezetimibe | Ezetimibe | 41 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | suppressed |
| Valsartan | Valsartan | 38 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 32 |
| Valacyclovir | Valacyclovir Hcl | 36 | 16 |
| Alendronate Sodium | Alendronate Sodium | 35 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | suppressed |
| Methocarbamol | Methocarbamol | 34 | 15 |
| Sertraline Hcl | Sertraline Hcl | 34 | 13 |
| Chlorthalidone | Chlorthalidone | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 23 |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Jardiance | Empagliflozin | 31 | suppressed |
| Acyclovir | Acyclovir | 30 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 30 | 18 |
| Glipizide | Glipizide | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 29 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 28 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 28 | 28 |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Ramipril | Ramipril | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Celecoxib | Celecoxib | 25 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 25 | suppressed |
| Famotidine | Famotidine | 24 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 21 |
| Estradiol | Estradiol | 21 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Prednisone | Prednisone | 21 | 16 |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Furosemide | Furosemide | 17 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Carisoprodol | Carisoprodol | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Potassium Chloride | Potassium Chloride | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Methylphenidate Er (La) | Methylphenidate Hcl | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 12 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $877.05 · 40 records | ABBVIE INC. | AIRSUPRA, AREXVY, CAPVAXIVE, Cologuard Collection Kit, Evoke, FARXIGA, Fluad, Flucelvax, GARDASIL 9, INCEPTIV, JOURNAVX, Kerendia, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, SHINGRIX, UBRELVY, Veozah, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error